1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Zymeworks’ HER2 Antibody Hits Target In Pivotal Biliary Tract Cancer Trial

First-In-Class Potential In Disease

 
• By Ayisha Sharma

The Canadian firm’s bispecific antibody asset improved response rates in advanced biliary tract cancer patients, potentially setting it up to become the first HER2-targeted drug approved for the disease.    

3D Animation of antibodies
Zanidatamab Is A Bispecific Antibody That Targets HER2 • Source: Shutterstock

Zymeworks, Inc.’s zanidatamab has impressed in a pivotal trial in HER2-amplified and expressing biliary tract cancer (BTC), sparking filing plans that could see it become the first HER2-targeted therapy for the disease.

Zanidatamab is a bispecific antibody candidate that can simultaneously bind two non-overlapping epitopes of HER2, triggering dual HER2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from R&D

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.